This study included women aged > 40 years (range, 40–43 years) with previous experience of POR or poor ovarian reserve (POSEIDON group 4) undergoing their first ART treatment in our institution between January 2009 and March 2014. These patients were given the option of using GH, but may or may not have elected to utilize GH during the cycle when initially offered (due to costs or other concerns). This cohort study evaluated 182 cycles with and 160 without GH supplementation.
This study enrolled patients who visited our ENT out-patient department with the primary complaint of tinnitus more than 6 months. A full medical history assessment was performed, and each patient underwent an otoscopic examination, a basic audiologic evaluation. A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
Data sets used, processed and referred in the manuscript are uploaded with reference to the figure number. and also checker board after image registration is uploaded. Following data sets can found,
1. CT sequence
2. MRI sequence
3. Registered MRI sequence
4. Fused CT and registered MRI sequence
5. Checker board image sequence after registration (If required before registration can be provided)
In the manuscript, slices can be found, attached are the whole sequence of the respective data set.